Iranian Company Makes Plasma-Derived Medicinal Products
With the support of the Innovation and Prosperity Fund of Iran and efforts of scientists at the knowledge-based company, the production capacity of blood plasma-derived products has increased and its production line has been expanded.
“Our company is the first and only blood plasma refinery in the Middle-East whose raw materials are human blood plasma from people who donate it voluntarily,” said Bardia Farzamfar, the managing director of the knowledge-based company.
“Products extracted from blood plasma are used to treat autoimmune diseases, hemophilia, or people who have lost blood for any reason and whose bodies need to compensate for the lost blood,” he added.
“The main products of our knowledge-based company are drugs like albumin and immunoglobulin (IVIG), which are used in the treatment of various diseases,” Farzamfar said.
“Our company has been producing and marketing albumin and immunoglobulin drugs for nearly three years. Recently, our company's research and development (R&D) team has also started making factor products and we are making efforts to produce and market them within the next two years,” he added.
Over 20 different proteins can be isolated for the production of plasma-derived medicinal products such as albumin, immunoglobulin, clotting factors, fibrinogens, etc.
Plasma-derived medicinal products (PDMPs) are prepared industrially from human plasma by pharmaceutical companies and include products like albumin, coagulation factors and immunoglobulins, which are life-saving therapeutics for several chronic and acute life-threatening diseases.
4155/v
